References
- Arai T, Miyoshi Y, Kim S J, et al (2008). Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol, 34, 734-8. https://doi.org/10.1016/j.ejso.2007.07.008
- Arteaga CL, Moulder SL, Yakes FM (2002). HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol, 29, 4-10.
- Baguley BC (2010). Multiple Drug Resistance Mechanisms in Cancer. Mol Biotechnol, 46, 308-16. https://doi.org/10.1007/s12033-010-9321-2
- Ballerini S, Bellincampi L, Bernardini S, et al (2003). Analysis of GSTP1-1 polymorphism using real-time polymerase chain reaction. Clinica Chimica Acta, 329, 127-32. https://doi.org/10.1016/S0009-8981(02)00422-9
- Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010). Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol, 7, 22-36. https://doi.org/10.1038/nrclinonc.2009.186
- Bhoo-Pathy N, Yip CH, Hartman M, et al (2013). Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer, 49, 703-9. https://doi.org/10.1016/j.ejca.2012.09.014
- Coughlin SS, Ekwueme DU (2009). Breast cancer as a global health concern. Cancer Epidemiol, 33, 315-8. https://doi.org/10.1016/j.canep.2009.10.003
- Dizdarevic S, Peters AM (2011). Imaging of multidrug resistance in cancer. Cancer Imaging, 11, 1-8. https://doi.org/10.1102/1470-7330.2011.0001
- Fromm MF (2002). The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev, 54, 1295-310. https://doi.org/10.1016/S0169-409X(02)00064-9
- Gu W, Fang FF, Li B, Cheng BB, Ling CQ (2012).Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. Asian Pac J Cancer Prev, 13, 4807-14. https://doi.org/10.7314/APJCP.2012.13.9.4807
- Kaira K, Takahashi T, Murakami H, et al (2013). The role of betaIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol, 18, 371-9. https://doi.org/10.1007/s10147-012-0386-8
- Kerr EH, Frederick PJ, Egger ME, et al (2013). Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Ann Surg Oncol, 20, 3059-65. https://doi.org/10.1245/s10434-013-2878-9
- Lloyd HH (1974). Combination chemotherapy: considerations for design and analysis. Cancer Chemother Rep 2, 4, 157-65.
- Lu L, Zhou D, Jiang X, et al (2012). Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/Adr: possible implication in the enhanced invasive ability. Eur Rev Med Pharmacol Sci, 16, 1271-9.
- Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C (2012). Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev, 38, 890-903. https://doi.org/10.1016/j.ctrv.2012.02.011
- Podolski-Renic A, Andelkovic T, Bankovic J, et al (2011). The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines. Biomed Pharmacother, 65, 345-53. https://doi.org/10.1016/j.biopha.2011.04.015
- Saeki T, Tsuruo T, Sato W, Nishikawsa K (2005). Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol, 56, 84-9. https://doi.org/10.1007/s00280-005-0106-4
- Saloustros E, Mavroudis D, Georgoulias V (2008). Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother, 9, 2603-16. https://doi.org/10.1517/14656566.9.15.2603
- Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 62, 220-41. https://doi.org/10.3322/caac.21149
- Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
- Smoter M, Bodnar L, Duchnowska R, et al (2011). The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol, 68, 553-7. https://doi.org/10.1007/s00280-011-1696-7
- Snow K, Judd W (1991). Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. Br J Cancer, 63, 17-28. https://doi.org/10.1038/bjc.1991.7
- Song YN, Guo XL, Zheng BB, et al (2011). Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTpi activity. Toxicology In Vitro, 25, 937-43. https://doi.org/10.1016/j.tiv.2011.03.002
- Urruticoechea A, Smith IE, Dowsett M (2005). Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 23, 7212-20. https://doi.org/10.1200/JCO.2005.07.501
- Yu ST, Chen TM, Chern JW, Tseng SY, Chen YH (2009). Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis. Anticancer Drugs, 20, 382-8. https://doi.org/10.1097/CAD.0b013e32832a2cd4
- Zhang W, Ding W, Chen Y, et al (2011). Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai), 43, 647-53. https://doi.org/10.1093/abbs/gmr050
- Zhao YX, Liang WQ, Wang Y, Liu DX (2011). Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells. Pharmazie, 66, 130-5.
- Zhou HL, Zheng YJ, Cheng XZ, et al (2013). Intercellular transfer of P-glycoprotein from the drug resistant human bladder cancer cell line BIU-87 does not require cell-to-cell contact. J Urol, 190, 1069-75. https://doi.org/10.1016/j.juro.2013.04.053
Cited by
- Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway vol.12, pp.1, 2012, https://doi.org/10.3892/mmr.2015.3468
- Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells vol.110, pp.8, 2014, https://doi.org/10.1038/bjc.2014.136
- Establishment and Partial Characterization of an Epirubicin-Resistant Gastric Cancer Cell Line with Upregulated ABCB1 vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6849
- Over-Expression of Beclin-1 Facilitates Acquired Resistance to Histone Deacetylase Inhibitor-Induced Apoptosis vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7913
- EGF Reverses Multi-drug Resistance via the p-ERK Pathway in HepG2/ADM and SMMC7721/ADM Hepatocellular Carcinoma Models vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2619
- Effects of Ribosomal Protein L39-L on the Drug Resistance Mechanisms of Lung Cancer A549 Cells vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3093
- Evodiamine Synergizes with Doxorubicin in the Treatment of Chemoresistant Human Breast Cancer without Inhibiting P-Glycoprotein vol.9, pp.5, 2014, https://doi.org/10.1371/journal.pone.0097512
- Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness vol.47, pp.1, 2015, https://doi.org/10.3892/ijo.2015.3019
- Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines vol.77, pp.6, 2015, https://doi.org/10.1292/jvms.14-0415
- Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer vol.142, pp.10, 2016, https://doi.org/10.1007/s00432-016-2167-7
- SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway vol.25, pp.3, 2017, https://doi.org/10.1080/1061186X.2016.1245307
- CLDN6 promotes chemoresistance through GSTP1 in human breast cancer vol.36, pp.1, 2017, https://doi.org/10.1186/s13046-017-0627-9
- Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy vol.37, pp.6, 2017, https://doi.org/10.3892/or.2017.5593
- SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells vol.50, pp.3, 2017, https://doi.org/10.3892/ijo.2017.3871
- A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis vol.35, pp.4, 2018, https://doi.org/10.1007/s11095-018-2370-0